title: In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia.
abstract: OBJECTIVE
  To investigate the specificity of in vivo amyloid imaging with [(11)C]-Pittsburgh Compound B (PIB) in Parkinson disease dementia (PDD).
  
  
  METHODS
  We performed detailed neuropathologic examination for 3 individuals with PDD who had PIB PET imaging within 15 months of death.
  
  
  RESULTS
  We observed elevated cortical uptake of [(11)C]-PIB on in vivo PET imaging in 2 of the 3 cases. At autopsy, all 3 individuals had abundant cortical Lewy bodies (Braak PD stage 6), and were classified as low-probability Alzheimer disease (AD) based on NIA-Reagan criteria. The 2 PIB-positive individuals had abundant diffuse Abeta plaques but only sparse neuritic plaques and intermediate neurofibrillary tangle pathology. The PIB-negative individual had rare diffuse plaques, no neuritic plaques, and low neurofibrillary tangle burden.
  
  
  CONCLUSIONS
  [(11)C]-Pittsburgh Compound B (PIB) PET is specific for fibrillar Abeta molecular pathology but not for pathologic diagnosis of comorbid Alzheimer disease in individuals with Parkinson disease dementia. The ability to specifically identify fibrillar Abeta amyloid in the setting of alpha-synucleinopathy makes [(11)C]-PIB PET a valuable tool for prospectively evaluating how the presence of Abeta amyloid influences the clinical course of dementia in patients with Lewy body disorders.
authors.affiliation: Department of Neurology and Pediatrics, 601 Elmwood Avenue, Box 673, University of Rochester Medical Center, Rochester, NY 14642, USA. michelle_burack@urmc.rochester.edu
authors.forename: M A
authors.initials: MA
authors.lastname: Burack
authors.forename: J
authors.initials: J
authors.lastname: Hartlein
authors.forename: H P
authors.initials: HP
authors.lastname: Flores
authors.forename: L
authors.initials: L
authors.lastname: Taylor-Reinwald
authors.forename: J S
authors.initials: JS
authors.lastname: Perlmutter
authors.forename: N J
authors.initials: NJ
authors.lastname: Cairns
mesh_terms: D000682:Amyloid / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000814:Aniline Compounds; D001344:Autopsy / Q000379:methods*; D001931:Brain Mapping; D002250:Carbon Radioisotopes; D002540:Cerebral Cortex / Q000473:pathology; D003704:Dementia / Q000150:complications / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D016631:Lewy Bodies / Q000000981:diagnostic imaging; D008297:Male; D008609:Mental Status Schedule; D016874:Neurofibrillary Tangles / Q000000981:diagnostic imaging / Q000473:pathology; D010300:Parkinson Disease / Q000150:complications / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods; D011446:Prospective Studies; D011485:Protein Binding; D012720:Severity of Illness Index; D013844:Thiazoles; D051844:alpha-Synuclein / Q000378:metabolism; D016875:tau Proteins / Q000378:metabolism
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000682:Amyloid; D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D002250:Carbon Radioisotopes; D013844:Thiazoles; D051844:alpha-Synuclein; D016875:tau Proteins